Inarigivir soproxil

N/A

Report date: 2025/03/18 17:01:46
NME

Base Information

Drug NameInarigivir soproxil
Drug Alias NameSB-9200GS-9992
ClassificationSmall molecules > Nucleosides and nucleotide derivtives
Mechanisms of ActionRetinoic acid-inducible gene I stimulantsNucleotide-binding oligomerization domain-containing protein 2 stimulants
TargetsNucleotide-binding oligomerization domain-containing protein 2Retinoic acid-inducible gene I
Therapy Area/IndicationsHepatitis, Viral, HumanHepatitis B, ChronicHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaSingaporeTaiwan +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSpring Bank
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesF-Star Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsHepatitis, Viral, HumanHepatitis B, ChronicHepatitis B

Other Information

ATC CodeN/A
Related LinksN/A